An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Patients with Atopic Dermatitis

What this Trial Is About

This research aims to evaluate the long-term safety and effectiveness of CM512 in adults with atopic dermatitis who have previously completed treatment in a parent CM512 study. The study is open-label and conducted at multiple centers, focusing on patients with this skin condition to gather extended data on the investigational treatment. Participants will receive CM512 through subcutaneous injection during the study. The design includes multiple experimental groups, and the study period spans up to 52 weeks, allowing researchers to observe long-term effects after prior treatments in earlier studies. This phase 2 study does not use blinding, and participants are randomized among the groups. During the study, participants will be monitored for adverse events and other safety measures for up to one year. Researchers will collect data on the treatment's impact and any side effects, ensuring thorough evaluation. Participants must have completed earlier parts of the CM512 parent studies to join, and they will be followed closely throughout the study duration which ends in December 2027.

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.